May 16, 2023 / 07:05PM GMT
Brian Abrahams - RBC Capital Markets - Moderator
All right. Good afternoon, everyone. Brian Abrahams, one of the senior biotech analysts here at RBC Capital Markets. Our next featured company is Xenon Pharmaceuticals represented by their CEO, Ian Mortimer; and their CFO, Sherry Aulin. So thanks so much for joining us.
Questions and Answers:
Brian Abrahams - RBC Capital Markets - ModeratorLots to talk about. And a lot of progress continues to be made with 1101. I want to maybe start with the bigger picture question on 1101. As you start to think about the opportunity for the drug post the successful Phase 2 X-TOLE data, I'm curious, the latest that you're hearing from your market research and from physicians for how 1101 can slot into that future treatment paradigm?
And maybe you could talk about the unmet need overall in epilepsy, in focal and generalized seizures. Just the numbers of patients, how plugged into treatment they are, where the failures are today, and where you're looking to focus the drug? And then we can go from there.
Trustpilot
